Neurotrophins Market

Neurotrophins Market - Global Market Share, Trends, Analysis and Forecast, 2023-2032
Frequently asked questions about this report

The neurotrophins market was estimated to be US$ 4.67 Billion in 2022.

The neurotrophins market is expected grow at a CAGR of 7.8% between 2023 to 2032.

The neurotrophins market is driven by several factors such as the increasing incidence of neurological disorders, the growing demand for personalized medicine, and the growing focus on the development of novel drugs.

Asia-Pacific region will lead the global neurotrophins market. In Asia-Pacific, there is a growing focus on developing new and innovative treatments for neurological disorders, and companies are investing in R&D to develop new treatments for these disorders.

The neurotrophins are largely used in the Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Parkinson’s Disease, and other applications.

Neurotrophins are widely used in hospitals for the treatment of a range of neurological disorders, and the growing demand for effective treatments for these disorders is driving the growth of the hospitals segment.

The fastest-growing segment of the neurotrophins market based on product is the Brain-Derived Neurotrophic Factor (BDNF) segment. This is due to the growing interest in the development of BDNF-based treatments for neurological disorders.

Major players operating in the global neurotrophins market include AbbVie (USA), Alcon (Switzerland), Allergan (Ireland), AstraZeneca (UK), BioMarin Pharmaceutical (USA), Bristol-Myers Squibb (USA), Eli Lilly and Company (USA), GlaxoSmithKline (UK), Johnson & Johnson (USA), Merck & Co. (USA), Novartis (Switzerland), Pfizer (USA), Roche (Switzerland), Sanofi (France), Teva Pharmaceutical Industries (Israel), and many more.